Oncolytics Biotech Inc. (ONC.TO)
| Previous Close | 1.3100 |
| Open | 1.2600 |
| Bid | 1.2600 x 0 |
| Ask | 1.2900 x 0 |
| Day's Range | 1.2600 - 1.2900 |
| 52 Week Range | 1.0600 - 3.5500 |
| Volume | |
| Avg. Volume | 33,288 |
| Market Cap | 72.816M |
| Beta (5Y Monthly) | 1.71 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4820 |
| Earnings Date | Aug 04, 2022 - Aug 08, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.42 |
- Baystreet
Stocks in play: Oncolytics Biotech Inc
Announced that the pancreatic cancer cohort of the multi-indication phase 1/2 GOBLET study has met the ...
- CNW Group
Oncolytics Biotech® Achieves Success Criteria for Efficacy in the Pancreatic Cancer Cohort of GOBLET
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the pancreatic cancer cohort of the multi-indication phase 1/2 GOBLET study has met the efficacy expansion criteria for Stage 1 of the trial. The data from the phase 1b portion of this cohort, which are featured in an abstract accepted for a poster presentation at the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2022, show a strong efficacy signal as evidenced by all patients achievi
- CNW Group
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders and Appoints James T. Parsons to its Board of Directors
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on Thursday, June 16, 2022. A total of 40.43% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting. Additionally, James T. Parsons was elected to the Oncolytics Biotech Board of Directors. Leonard (Leon) Kruimer did not stand for re-election as a director at the AGM.
